Sponsor pipeline

Roche / Genentech clinical trial pipeline

Get alerts when Roche / Genentech's trials change

256 active trials 100 recruiting 94 Phase 3 47 disease areas 105 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days showing 55 of 105 changes on 20 trials

2026-10-06
Primary completion pushed from Aug 31, 2026 to May 25, 2028
Trial sites reduced: 178 → 171 locations
Completion pushed from Mar 31, 2029 to Aug 31, 2029
NCT05797610 A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants… · Phase 3
2026-10-02
Primary completion pushed from Nov 27, 2026 to Feb 5, 2028
Enrollment increased: 240 → 330 participants
Trial sites reduced: 50 → 46 locations
Completion pushed from Nov 27, 2026 to Feb 5, 2028
Trial arms changed: 9 → 12
NCT07112872 A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People… · Phase 2
2026-09-15
Primary completion pushed from Feb 19, 2027 to Apr 20, 2028
Enrollment closed, study ongoing
Trial sites reduced: 352 → 311 locations
NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… · Phase 3
2026-09-24
Primary completion pushed from Jun 30, 2026 to Jun 30, 2027
Completion pushed from Jun 30, 2026 to Jun 30, 2027
NCT02650401 Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or… · Phase 1/2
2026-09-12
Primary completion pushed from Jul 31, 2031 to Apr 30, 2032
Completion pushed from Jul 31, 2031 to Apr 30, 2032
NCT07226206 A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A · Phase 1/2
2026-09-12
Primary completion pushed from Dec 31, 2026 to Jun 17, 2030
Primary endpoint(s) modified
Enrollment closed, study ongoing
Enrollment increased: 40 → 240 participants
Completion pushed from Dec 31, 2026 to Jun 17, 2030
Interventions modified
Trial arms changed: 2 → 3
NCT07342114 A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of… · Phase 1
2026-10-10
Primary endpoint(s) modified
NCT07749157 A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple… · Phase 1
2026-10-02
Primary endpoint(s) modified
NCT05199688 A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and… · Phase 3
2026-09-29
Primary endpoint(s) modified
Results posted: 2026-09-28
Trial sites reduced: 148 → 141 locations
NCT04660344 A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk… · Phase 3
2026-09-22
Phase changed: Phase 1/2 → Phase 1
Trial completed
NCT06693908 A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate… · Phase 1
2026-10-08
Recruitment opened
NCT07843485 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… · Phase 3
2026-10-08
Recruitment opened
Trial sites expanded: 0 → 3 locations
NCT07843498 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… · Phase 3
2026-10-08
Recruitment opened
Trial sites expanded: 0 → 3 locations
NCT07843472 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… · Phase 3
2026-10-03
Enrollment closed, study ongoing
Trial sites reduced: 200 → 168 locations
Primary completion moved earlier from Jan 30, 2027 to Oct 29, 2026
NCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also… · Phase 3
2026-10-07
Enrollment closed, study ongoing
Trial sites reduced: 18 → 9 locations
NCT06624085 A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in… · Phase 1
2026-10-01
Trial completed
Trial sites expanded: 155 → 216 locations
Study completion date changed from estimate of Aug 31, 2027 to Aug 26, 2026
NCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best… · Phase 3
2026-09-26
Enrollment closed, study ongoing
Final enrollment: 1101 participants (planned 800)
Primary completion moved earlier from Jun 7, 2028 to Feb 16, 2028
Completion moved earlier from Jun 7, 2028 to Feb 16, 2028
NCT07169578 A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease · Phase 3
2026-09-26
Enrollment closed, study ongoing
Trial sites reduced: 150 → 147 locations
Final enrollment: 1060 participants (planned 800)
Primary completion moved earlier from Jun 7, 2028 to Feb 16, 2028
Completion moved earlier from Jun 7, 2028 to Feb 16, 2028
NCT07170150 A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease · Phase 3
2026-09-19
Trial completed
Study completion date changed from estimate of Jun 30, 2026 to Nov 17, 2025
NCT04665856 Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in… · Phase 3
2026-09-15
Trial completed
Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026
NCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable… · Phase 3

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-09 NCT07867262 A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant… Phase 1 Not Yet Recruiting
2026-10-05 NCT07859085 A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in… Phase 1 Not Yet Recruiting
2026-10-01 NCT07851259 A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic… Phase 2 Not Yet Recruiting
2026-09-29 NCT07846683 A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in… Phase 3 Not Yet Recruiting
2026-09-28 NCT07843472 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Phase 3 Recruiting
2026-09-28 NCT07843485 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Phase 3 Recruiting
2026-09-28 NCT07843498 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Phase 3 Recruiting
2026-09-24 NCT07838194 Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and… Phase 3 Not Yet Recruiting
2026-09-22 NCT07835243 A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of… Phase 1 Not Yet Recruiting
2026-09-18 NCT07827573 A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer… Phase 3 Not Yet Recruiting

Active trials by phase

Phase 1
55
Phase 1/2
25
Phase 2
52
Phase 2/3
4
Phase 3
90
Phase 4
10
Not charted: 20 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 256

NCT IDTitleConditionStatusUpdated
Phase 4
NCT06274515 A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies Breast Cancer Recruiting 2026-10-06
NCT04853251 A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… Neovascular Age-related Macular Degeneration Recruiting 2026-10-02
NCT05861986 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… Muscular Atrophy, Spinal Recruiting 2026-10-02
NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… Multiple Sclerosis Recruiting 2026-09-30
NCT05861999 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… Muscular Atrophy, Spinal Recruiting 2026-09-10
NCT07483450 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Relapsing Multiple Sclerosis Active, Not Recruiting 2026-09-30
NCT05232929 Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) Spinal Muscular Atrophy Active, Not Recruiting 2026-09-09
NCT05224102 A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… Diabetic Macular Edema Active, Not Recruiting 2026-08-25
NCT06795048 A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… Neovascular Age-related Macular Degeneration (nAMD) Active, Not Recruiting 2026-07-31
NCT05181618 A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… Severe Hemophilia A Active, Not Recruiting 2026-07-27
Phase 3
NCT06998524 A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von… Von Willebrand Disease, Type 3 Recruiting 2026-10-09
NCT07177352 Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… Alzheimers Disease Recruiting 2026-10-09
NCT07541079 A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant… Early Breast Cancer Recruiting 2026-10-09
NCT07670416 A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or… Obesity Recruiting 2026-10-08
NCT07843472 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Obesity or Overweight Recruiting 2026-10-07
NCT07843485 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Obesity or Overweight Recruiting 2026-10-07
NCT07843498 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… Obesity or Overweight Recruiting 2026-10-07
NCT06084936 A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… Lymphoma Recruiting 2026-10-06
NCT06790693 A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and… Breast Cancer Recruiting 2026-10-06
NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus… Non-Small Cell Lung Cancer Recruiting 2026-10-06
NCT07158242 A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121)… Moderately to Severely Active Ulcerative Colitis Recruiting 2026-10-06
NCT07174310 A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in… Parkinson's Disease Recruiting 2026-10-06
NCT07298421 A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for… Moderately to Severely Active Crohns Disease Recruiting 2026-10-06
NCT07416604 A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in… Hemophilia A Recruiting 2026-10-06
NCT05862285 A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… Cancer Recruiting 2026-10-02
See all 256 active Roche / Genentech trials with filters →

Disease areas by active trials, top 10 of 47

Breast Cancer (30) · Multiple Sclerosis (24) · Lung Cancer (18) · Non-Small Cell Lung Cancer (NSCLC) (17) · Non-Hodgkin Lymphoma (13) · Obesity (11) · Multiple Myeloma (10) · Alzheimer's Disease (8) · Colorectal Cancer (7) · Diabetes (7)

Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free